News and commentary from the world of gastroenterology and hepatology ...

The ‘TL1A’ messenger protein of the immune system triggers gut-to-bone marrow reaction, increasing the colorectal cancer risk ...

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

A newly uncovered immune chain reaction in the gut may explain why people with inflammatory bowel disease face a much higher ...

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in ...

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone ...

For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense stress are often followed by worsening symptoms or full-blown disease flares.

German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease treatment from China's Simcere ...

In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.

A chain of immune reactions in the gut - driven by a key signaling protein and a surge of white blood cells from the bone marrow - may help explain ...

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in ...